These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Gharbiya M; Allievi F; Mazzeo L; Gabrieli CB Am J Ophthalmol; 2009 Jan; 147(1):84-93.e1. PubMed ID: 18774547 [TBL] [Abstract][Full Text] [Related]
24. Twenty-four-month outcomes of inflammatory choroidal neovascularisation treated with intravitreal anti-vascular endothelial growth factors: a comparison between two treatment regimens. Invernizzi A; Pichi F; Symes R; Zagora S; Agarwal AK; Nguyen P; Erba S; Xhepa A; De Simone L; Cimino L; Gillies MC; McCluskey PJ Br J Ophthalmol; 2020 Aug; 104(8):1052-1056. PubMed ID: 31744798 [TBL] [Abstract][Full Text] [Related]
25. Intravitreal ziv-aflibercept for the treatment of choroidal neovascularisation associated with conditions other than age-related macular degeneration. Braimah IZ; Stewart M; Videkar C; Dedhia CJ; Chhablani J; Br J Ophthalmol; 2017 Sep; 101(9):1201-1205. PubMed ID: 28119292 [TBL] [Abstract][Full Text] [Related]
26. Long-Term Analysis of Clinical Features and Treatment Outcomes of Inflammatory Choroidal Neovascularization. Kim M; Lee J; Park YG; Park YH Am J Ophthalmol; 2022 Jan; 233():18-29. PubMed ID: 34298010 [TBL] [Abstract][Full Text] [Related]
27. Intravitreal bevacizumab as first local treatment for uveitis-related choroidal neovascularization: long-term results. Julián K; Terrada C; Fardeau C; Cassoux N; Français C; LeHoang P; Bodaghi B Acta Ophthalmol; 2011 Mar; 89(2):179-84. PubMed ID: 21348964 [TBL] [Abstract][Full Text] [Related]
28. Combined photodynamic therapy with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy: long-term visual outcome. Kang HM; Koh HJ; Lee CS; Lee SC Am J Ophthalmol; 2014 Mar; 157(3):598-606.e1. PubMed ID: 24269378 [TBL] [Abstract][Full Text] [Related]
29. Intravitreal bevacizumab for treatment of subfoveal idiopathic choroidal neovascularization: results of a 1-year prospective trial. Zhang H; Liu ZL; Sun P; Gu F Am J Ophthalmol; 2012 Feb; 153(2):300-306.e1. PubMed ID: 21982109 [TBL] [Abstract][Full Text] [Related]
30. Bevacizumab for choroidal neovascularization related to inflammatory diseases. Kramer M; Axer-Siegel R; Jaouni T; Reich E; Hemo I; Priel E; Averbukh E; Ehrlich R; Chowers I; Weinberger D; Amer R Retina; 2010 Jun; 30(6):938-44. PubMed ID: 20168273 [TBL] [Abstract][Full Text] [Related]
31. Comparison of photodynamic therapy, ranibizumab/bevacizumab or combination in the treatment of myopic choroidal neovascularisation: a 9-year-study from a single centre. Rishi P; Rishi E; Bhende M; Agarwal V; Vyas CH; Valiveti M; Bhende P; Rao C; Susvar P; Sen P; Raman R; Khetan V; Murali V; Ratra D; Sharma T Br J Ophthalmol; 2016 Oct; 100(10):1337-40. PubMed ID: 26792945 [TBL] [Abstract][Full Text] [Related]
32. Intravitreal Bevacizumab for Nonsubfoveal Choroidal Neovascularization Associated With Angioid Streaks: 3-Year Follow-up Study. Iacono P; Battaglia Parodi M; La Spina C; Bandello F Am J Ophthalmol; 2016 May; 165():174-8. PubMed ID: 27013066 [TBL] [Abstract][Full Text] [Related]
34. Intravitreal Bevacizumab for Choroidal Neovascularization Associated with Angioid Streaks: Long-term Results. Lekha T; Prasad HN; Sarwate RN; Patel M; Karthikeyan S Middle East Afr J Ophthalmol; 2017; 24(3):136-142. PubMed ID: 29279654 [TBL] [Abstract][Full Text] [Related]
35. Outcomes by Baseline Choroidal Neovascularization Features in Age-Related Macular Degeneration: A Post Hoc Analysis of the VIEW Studies. Steinle NC; Du W; Gibson A; Saroj N Ophthalmol Retina; 2021 Feb; 5(2):141-150. PubMed ID: 32652314 [TBL] [Abstract][Full Text] [Related]